Study S2312

S2312 is a study for people with castrate-resistant #prostatecancer. It tests a combination of chemo drugs, #carboplatin and #cabazitaxel.
SWOG.org/S2312. Or call 1-800-4-CANCER. Ask about S2312. #pcsm

S2312: A research study for people with castrate-resistant prostate cancer

S2312 is a study for people with castrate-resistant #prostatecancer. It tests a combination of
chemo drugs, #carboplatin and #cabazitaxel. Visit SWOG.org/S2312. Or call 1-800-4-CANCER. Ask
about S2312. #pcsm

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prost... These results support the use of [177Lu]Lu-PSMA-617 as an alternative to cabazitaxel for PSMA-positive metastatic castration-resistant prostate cancer progressing after docetaxel. We did not find evid...

Great to see the @anzuptrials.bsky.social #TheraP #ClinicalTrial overall survival data published today in Lancet Oncology: #LuPSMA vs #cabazitaxel in #ProstateCancer

www.thelancet.com/journals/lan...